BAD and lung cancer: Administration of Fisetin resulted in the decrease of antiapoptotic proteins (such as Bcl-2 and Bcl XL), the increase of proapoptotic proteins (such as Bax and bad), and activation of the caspase-3 signaling pathway in lung cancer cells [24].